Loading…
MINT-ABACAVIR is a brand name for Abacavir, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
1 Dosing Considerations 11/2021 7 WARNINGS AND PRECAUTIONS, General 11/2021 7 WARNINGS AND PRECAUTIONS, Hypersensitivity Reactions 11/2021 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES .....................................................................................
2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 4 1.
INDICATIONS ......................................................................................................................... 1 Pediatrics.......................................................................................................................
2 Geriatrics....................................................................................................................... 4 2. CONTRAINDICATIONS ........................................................................................................
4 3. SERIOUS WARNINGS AND PRECAUTIONS BOX .......................................................... 5 4. DOSAGE AND ADMINISTRATION .................................................................................... 1 Dosing Considerations ..................................................................................................
2 Recommended Dose and Dosage Adjustment .............................................................. 3 Missed Dose.................................................................................................................. 7 5.
OVERDOSAGE ........................................................................................................................ 7 6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ....................... 8 7. WARNINGS AND PRECAUTIONS ......................................................................................
1 Special Populations..................................................................................................... 1 Pregnant Women .....................................................................................................
2 Breast-feeding .......................................................................................................... 3 Pediatrics..................................................................................................................
4 Geriatrics.................................................................................................................. 14 8. ADVERSE REACTIONS ......................................................................................................
1 Adverse Drug Reaction Overview .............................................................................. 2 Clinical Trial Adverse Reactions ................................................................................ 1 Clinical Trials Adverse Reactions - Pediatrics ........................................................
, General 11/2021 7 WARNINGS AND PRECAUTIONS, Hypersensitivity Reactions 11/2021 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES ..................................................................................... 2 TABLE OF CONTENTS .............................................................................................................
2 PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 4 1. INDICATIONS .........................................................................................................................
1 Pediatrics....................................................................................................................... 2 Geriatrics.......................................................................................................................
4 2. CONTRAINDICATIONS ........................................................................................................ 4 3. SERIOUS WARNINGS AND PRECAUTIONS BOX .......................................................... 5 4. DOSAGE AND ADMINISTRATION ....................................................................................
1 Dosing Considerations .................................................................................................. 2 Recommended Dose and Dosage Adjustment .............................................................. 3 Missed Dose..................................................................................................................
7 5. OVERDOSAGE ........................................................................................................................ 7 6. DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ....................... 8 7. WARNINGS AND PRECAUTIONS ......................................................................................
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Abacavir in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
3 Less common clinical trial adverse reactions ............................................................. 4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data ..............................................................................................................
5 Post-Market Adverse Reactions ................................................................................. 6 Description of Abacavir Hypersensitivity Adverse Reactions ................................... 18 9. DRUG INTERACTIONS.......................................................................................................
1 Overview..................................................................................................................... 2 Drug-Drug Interactions...............................................................................................
3 Drug-Food Interactions............................................................................................... 4 Drug-Herb Interactions ...............................................................................................
5 Drug-Laboratory Test Interactions ............................................................................. 21 10. CLINICAL PHARMACOLOGY........................................................................................ 1 Mechanism of Action ...............................................................................................
2 Pharmacokinetics ...................................................................................................... 21 11. STORAGE, STABILITY AND DISPOSAL ...................................................................... 24 12.
SPECIAL HANDLING INSTRUCTIONS ........................................................................ 24 PART II: SCIENTIFIC INFORMATION ............................................................................... 25 13. PHARMACEUTICAL INFORMATION ..........................................................................
25 14. CLINICAL TRIALS ............................................................................................................ 1 Trial Design and Study Demographics .....................................................................
2 Study Results ............................................................................................................ 3 Comparative Bioavailability Studies ........................................................................
28 15. MICROBIOLOGY ............................................................................................................... 29 16. NON-CLINICAL TOXICOLOGY .....................................................................................
31 17. SUPPORTING PRODUCT MONOGRAPHS […]
1 Special Populations..................................................................................................... 1 Pregnant Women .....................................................................................................
2 Breast-feeding .......................................................................................................... 3 Pediatrics..................................................................................................................
4 Geriatrics.................................................................................................................. 14 8. ADVERSE REACTIONS ......................................................................................................
1 Adverse Drug Reaction Overview .............................................................................. 2 Clinical Trial Adverse Reactions ................................................................................ 1 Clinical Trials Adverse Reactions - Pediatrics ........................................................
3 Less common clinical trial adverse reactions ............................................................. 4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data ..............................................................................................................
5 Post-Market Adverse Reactions ................................................................................. 6 Description of Abacavir Hypersensitivity Adverse Reactions ................................... 18 9. DRUG INTERACTIONS.......................................................................................................
1 Overview..................................................................................................................... 2 Drug-Drug Interactions...............................................................................................
3 Drug-Food Interactions............................................................................................... 4 Drug-Herb Interactions ...............................................................................................
5 Drug-Laboratory Test Interactions ............................................................................. 21 10. CLINICAL PHARMACOLOGY........................................................................................ 1 Mechanism of Action ...............................................................................................
2 Pharmacokinetics ...................................................................................................... 21 11. STORAGE, STABILITY AND DISPOSAL ...................................................................... 24 12.
SPECIAL HANDLING INSTRUCTIONS ........................................................................ 24 PART II: SCIENTIFIC INFORMATION ............................................................................... 25 13. PHARMACEUTICAL INFORMATION ..........................................................................
25 14. CLINICAL TRIALS ............................................................................................................ 1 Trial Design and Study Demographics .....................................................................
2 Study Results ............................................................................................................ 3 Comparative Bioavailability Studies ........................................................................
28 15. MICROBIOLOGY ............................................................................................................... 29 16. NON-CLINICAL TOXICOLOGY .....................................................................................
31 17. SUPPORTING PRODUCT MONOGRAPHS ................................................................... […]